Table 5.
Multivariate analysis for the effect of clinicopathologic parameters and PD-L1 expression on overall survival
| Clinicopathologic parameter | Hazard ratio (95 % CI) | p-value |
|---|---|---|
| Age (per 1 year) | 1.033 (1.022–1.044) | <.0001 |
| Tumor stage | ||
| pT1 (reference) | 1 | |
| pT2 | 1.622 (1.084–2.427) | 0.0186 |
| pT3 | 1.621 (0.869–3.026) | 0.1290 |
| pT4 | 2.185 (1.334–3.578) | 0.0019 |
| Lymph node involvement | ||
| pN1 (reference) | 1 | |
| pN1 | 1.452 (1.071–1.968) | 0.0165 |
| pN2 | 1.921 (1.283–2.875) | 0.0015 |
| Tumor grade | ||
| BRE grade 1 (reference) | 1 | |
| 2 | 1.874 (1.201–2.923) | 0.0057 |
| 3 | 2.537 (1.604–4.014) | <.0001 |
| PD-L1 expression, all cases | ||
| PD-L1-negative (reference) | 1 | |
| PD-L1-positive | 3.063 (2.318–4.047) | <.0001 |
| PD1 expression, by intrinsic subtype | ||
| Luminal A (reference) | 1 | |
| Luminal B (HER2−) | 1.542 (0.874–2.724) | 0.1352 |
| Luminal B (HER2+) | 1.484 (0.764–2.882) | 0.2437 |
| Her2 type | 1.091 (0.530–2.247) | 0.8123 |
| Basal-like | 2.394 (1.294–4.430) | 0.0054 |